The Life Sciences industry, including pharmaceuticals, biotechnology, medical devices and diagnostics, has long relied on mergers and acquisitions (M&A) to drive innovation, expand portfolios and respond to evolving market demands. Over the past decade, M&A activity has been shaped not only by scientific breakthroughs and regulatory shifts, but also by digital transformation and the need to address upcoming patent cliffs.
Big pharma continues to focus on acquiring pipeline assets, particularly late-stage opportunities in oncology, immunology, inflammation, obesity and metabolic disease, cardiovascular disease and neuroscience. In medtech, M&A activity is expected to accelerate around diagnostics, cardiovascular technologies, AI-enabled analytics and connected care. Companies are also continuing to prune non-core assets through major portfolio moves and divestitures.
M&A activity declined in 2024, largely due to high interest rates, tighter financing conditions, geopolitical uncertainty and supply chain risks. However, the market began to show signs of recovery in 2025, not through broad-based consolidation, but through fewer, larger and more strategic transactions. Deal volume remained muted, yet average deal value per transaction increased, reflecting a shift from volume-driven to value-driven M&A.
Looking ahead, 2026 could be a breakout year for Life Sciences dealmaking. Even so, expectations remain centered on disciplined, strategic deals designed to fill pipeline gaps, strengthen core portfolios and support long-term growth rather than widespread consolidation.
Strategic Rationale Behind Deals
The strong rebound in Life Sciences M&A in 2025 was driven by several structural and strategic factors. One of the most important was the growing patent cliff, where many blockbuster drugs are nearing the end of their exclusivity period, pushing pharmaceutical companies to acquire new assets to replace declining revenues. Firms also showed a clear preference for de-risked, late-stage or commercial assets, which offer more predictable returns compared to early-stage research.
The rapid pace of innovation in areas such as oncology, biologics and advanced therapies intensified competition, encouraging companies to pursue acquisitions to stay competitive. Together, these factors created a strong strategic urgency, leading to larger and more targeted M&A activity in 2025.
Deal Structures
In Life Sciences, deal structures are designed to balance value certainty against scientific, regulatory, reimbursement and commercial uncertainty. Recent transactions show that structure being used for targeted, theme-driven portfolio building. For example, Johnson & Johnson’s 2025 agreement to acquire Intra-Cellular Therapies strengthened its CNS and neuropsychiatry position. Pfizer’s 2025 acquisition of Metsera added obesity and cardiometabolic pipeline assets and included a contingent value right (CVR) to share clinical and regulatory risk. Novartis’ agreement to acquire Avidity Biosciences further reflects current appetite for RNA-based, late-stage neuroscience assets.
These examples show how 2025 and 2026 Life Sciences M&A activity is increasingly focused on disciplined, strategic acquisitions in high-priority areas such as oncology, obesity/metabolic disease and AI-enabled drug development.
Mergers, spin-offs and carve-outs are also important when companies want continuity of ownership, tax efficiency or sharper strategic focus. Pfizer’s separation of Upjohn and its all-stock Reverse Morris Trust combination with Mylan to form Viatris remains a useful example of separating mature assets while preserving shareholder participation. More recent medtech and Life Sciences portfolio actions show how this approach has evolved: 3M’s spin-off of Solventum created a focused healthcare company. Solventum later sold its Purification & Filtration business to Thermo Fisher for $4 billion to simplify the portfolio and reduce debt.
AI and data capabilities are also becoming part of the deal thesis, as shown by Thermo Fisher’s agreement to acquire Clario to expand digital endpoint-data and AI-enabled clinical research capabilities. To manage valuation gaps, Life Sciences deals continue to rely on earnouts and CVRs. For example, Brickell’s deal with Botanix used milestone and sales-based earnouts, and Bristol-Myers Squibb’s acquisition of Celgene used a CVR tied to future regulatory milestones. Overall, risk-sharing remains central to these transactions, with parties allocating uncertainty through contingent payments, milestone triggers, profit-sharing, financing support, regulatory covenants, termination protections and post-closing carve-out obligations.
M&A Deals and What They Signal
The pharma and biotech M&A landscape is being shaped by the need for innovation, portfolio renewal and access to advanced technologies. As large pharmaceutical companies face patent cliffs, pricing pressure and rising R&D costs, deal activity is increasingly focused on acquiring high-value biotech assets, emerging technology platforms and global innovation capabilities.
Big Pharma is acquiring biotech to fill pipeline gaps: Large pharma companies are facing major patent expirations and revenue pressure, so they are buying biotech assets to access new drugs, platforms and late-stage candidates. Oncology remains central, but interest is also rising in immunology, neuroscience, rare disease, metabolic disease, radiopharmaceuticals and cell therapies.
AI, genomics, diagnostics and digital health are becoming core deal targets: M&A is no longer only about molecules. Companies are acquiring AI platforms, genomic data capabilities, diagnostics, clinical-trial technology and digital health tools to improve drug discovery, patient selection, trials and precision medicine.
Cross-border deals are increasing: Pharma companies are sourcing more innovation globally, especially from China, Japan and Europe. China has become a major source of biotech innovation, but geopolitical and regulatory risks are pushing companies toward licensing, co-development, option deals and milestone-based structures rather than full acquisitions alone.
Regulatory and antitrust scrutiny is intensifying: Regulators are examining deals more closely, especially where there are pipeline overlaps, market concentration, control over key technologies, data assets or AI-enabled healthcare tools. Buyers now need to plan for antitrust, data privacy, national security and AI governance risks early in the deal process.
The following chart shows the most recent M&A activity and its impact on the industry.
Table 1: Core M&A Deals 2025-2026
Deal | Segment | Announced / Completed | Deal Size / Structure | What It Signals |
| Johnson & Johnson / Intra-Cellular Therapies | Biopharma | Jan 13, 2025 / Apr 2, 2025 | $132 per share in cash; about $14.6B equity value | De-risked commercial assets with pipeline optionality still command strong premiums. |
| Zimmer Biomet / Paragon 28 | Medtech | Jan 28, 2025 / Apr 21, 2025 | $13 per share in cash plus a CVR up to $1; about $1.1B equity value / $1.2B enterprise value | Bolt-on acquisitions are using contingent value to preserve price discipline. |
| BioMarin / Inozyme Pharma | Biopharma | May 16, 2025 / July 1, 2025 | $4.00 per share in cash; about $270M total consideration | Micro-cap or distressed targets can show very high headline premiums despite modest check sizes. |
| Sanofi / Blueprint Medicines | Biopharma | June 2, 2025 / July 18, 2025 | $129 per share in cash plus a CVR up to $6; about $9.1B upfront / $9.5B including CVR. | CVRs are back as a biotech valuation bridge when upside exists but not fully de-risked. |
| Waters / BD Biosciences & Diagnostic Solutions | Diagnostics / life-science tools | July 14, 2025 / Feb 9, 2026 | $17.5B Reverse Morris Trust; BD gets approximately $4B cash | Tax-efficient separations and combinations remain active in diagnostics and life-science tools. |
| Abbott / Exact Sciences | Diagnostics | Nov 20, 2025 / Mar 23, 2026 | $105 per share in cash; about $21B equity value | Scaled testing franchises with recurring revenue can still support mega-deal pricing. |
Life Science deals announced in 2025 point to a selective but still ambitious M&A market. The following three reasons explain:
Mega-deals are back, but they are highly selective. Large deals have returned in areas in which buyers can add category leadership, de-risked revenue and clear portfolio adjacency. The deals like Exact Sciences and Intra-Cellular were both big deals, but each filled a focused strategic gap rather than representing broad conglomerate expansion.
Examples like Zimmer/Paragon and BioMarin/Inozyme Care highlight the presence of bolt-on acquisitions vs carve outs, as these narrower deals offer clearer commercial fit and lower integration complexity. That suggests boards are still more comfortable underwriting deals where synergies, channel overlap or franchise expansion are easier to explain and execute.
Valuation trends and premium shifts show that buyers remain selective, with some medtech deals seeing lower premiums (about 8% - 17%), while others like Blueprint were moderate (around 27% - 40%), and bigger, more attractive assets like Exact Sciences and Intra-Cellular saw higher premiums (50% - 60%). In some cases, like Inozyme, the premium looked very high because the company’s stock price was already very low. The main point is that buyers are being selective. They are willing to pay more for high-quality, lower-risk assets with proven revenue, but they often use tools like CVRs (extra payments later) to avoid paying the full price upfront when future success is still uncertain.
Risks and Challenges
Life Sciences M&A can create substantial value, but the sector carries risk profiles that are more complex than many other industries because transaction success depends on science, regulation, manufacturing, reimbursement, data and post-close execution. The most important risks are not limited to deal price; they also include whether the buyer can preserve innovation, accelerate development and convert the target asset into durable commercial value.
Life Sciences companies are facing one or more of the following six risks:
Integration and cultural alignment: Scientific and entrepreneurial biotech cultures do not always fit easily into large pharma or medtech operating models. Buyers need to protect the speed, decision rights and technical talent that made the target attractive while still integrating finance, quality, compliance, drug safety monitoring, cybersecurity and commercial operations. Poor cultural integration can slow development timelines, drive key-talent loss or dilute the innovation thesis that justified the acquisition.
Clinical and regulatory uncertainty: Even late-stage assets can fail to meet clinical endpoints, encounter safety concerns or face unexpected regulatory questions. In medtech, diagnostics and digital health, buyers must also evaluate product approvals, quality systems, clinical evidence, reimbursement status and whether international regulatory requirements are aligned. The risk is especially high when the deal value depends on a narrow set of pipeline milestones.
Overvaluation and pipeline risk: Competition for de-risked assets can push prices above what future cash flows support, especially in oncology, immunology, cardiometabolic disease, rare disease and advanced therapies. Buyers may be tempted to pay strategic premiums to solve patent-cliff pressure, but the return depends on launch timing, label breadth, market access, pricing, physician adoption and manufacturing readiness. CVRs, earnouts, options and staged licensing can help bridge valuation gaps, but they do not eliminate execution risk.
Technology, data and AI risk: As more deals target AI-enabled discovery, genomics, diagnostics and digital health, diligence must extend beyond the product to the data assets, algorithms, model governance, interoperability, cybersecurity, privacy rights and explainability of the technology. A platform that looks attractive commercially may carry hidden risks if the training data, consent structure, data provenance or regulatory pathway is weak.
Supply chain and manufacturing resilience: Biologics, cell and gene therapies, radiopharmaceuticals and specialized diagnostics often require complex manufacturing, cold-chain logistics, scarce raw materials, specialized facilities or contract development and manufacturing organization (CDMO) dependencies. Buyers must understand whether the target can scale reliably, whether supply is geographically exposed and whether quality systems can support global growth after close.
Antitrust, pricing and policy scrutiny: Large transactions, platform consolidation, overlapping pipelines and control over key technologies can attract more regulatory scrutiny. In addition, drug pricing, reimbursement, tariffs, national-security review and data-governance requirements can affect deal certainty and post-close economics. Successful acquirers now address regulatory strategy, remedy planning and public-policy risk earlier in the process.
Future Outlook
Over the next three to five years, Life Sciences M&A is likely to remain active but selective. The market is moving away from broad volume-driven dealmaking and toward targeted acquisitions that solve specific portfolio, pipeline, technology or commercial capability gaps. Buyers will continue to focus on assets that are scientifically differentiated, closer to clinical or commercial proof, and capable of addressing revenue pressure from upcoming loss-of-exclusivity events.
Below are some examples of impact areas:
Pipeline renewal will remain the primary driver: Large pharmaceutical companies will continue using M&A, licensing, option deals and co-development structures to replenish pipelines and offset patent-cliff exposure. The strongest demand will likely be for late-stage or commercial assets where clinical data, regulatory path and commercial opportunities are clearer.
Therapeutic focus will broaden beyond oncology: Oncology will remain a major deal category, but capital will increasingly flow into immunology, neuroscience, rare disease, cardiometabolic disease, radiopharmaceuticals and specialty areas with high unmet need and differentiated clinical profiles. Buyers will prioritize assets that can reset the standard of care or extend leadership in an existing therapeutic franchise.
Advanced therapies and precision medicine will continue to attract capital: Cell and gene therapy, RNA-based medicines, antibody-drug conjugates, radioligands, biologics, companion diagnostics and biomarker-led development will remain important acquisition themes. However, enterprises will need to evaluate these assets with greater discipline around durability of response, manufacturing scalability, patient access and reimbursement.
AI, data and digital health will become strategic infrastructure: AI-enabled discovery, clinical trial analytics, real-world evidence, genomic data, diagnostics and patient engagement tools will increasingly be viewed as capabilities that accelerate development and improve commercial precision. Rather than acquiring technology for novelty, buyers will look for platforms that produce measurable improvements in trial design, patient identification, regulatory confidence or launch performance.
Cross-border and alternative structures will increase: Innovation will remain globally distributed, with continued interest in China, Japan, Europe and emerging biotech hubs. Because geopolitical, IP, data and supply-chain risk can complicate outright acquisitions, more companies are likely to use licensing, regional rights, joint development, options, royalties, minority investments and CVRs to access innovation while managing risk.
Diligence will become faster and more data-driven: Buyers will use AI-enabled diligence, scenario modeling, probability-of-technical-and-regulatory-success analysis and value-creation planning earlier in the process. The winning acquirers will not simply identify good science; they will understand how quickly the asset can be developed, approved, manufactured, reimbursed, launched and integrated.
Overall, the next wave of M&A is expected to reward disciplined buyers that can combine scientific selectivity with execution capability. The most attractive targets will be those that offer clear differentiation, credible data, strong intellectual property, manageable regulatory risk and a path to commercial scale.
Conclusion
M&A will remain a core strategic tool for Life Sciences companies because it allows buyers to access innovation faster than internal development alone. The sector is entering a period in which patent-cliff pressure, scientific breakthroughs, digital transformation and portfolio reshaping are converging. As a result, deals are becoming more targeted, more data-driven and more dependent on execution discipline.
For investors, the strongest opportunities will come from companies with differentiated science, credible evidence, strong intellectual property and multiple paths to value creation. For strategic acquirers, the challenge will be to balance urgency with discipline: paying enough to secure scarce innovation while avoiding deals that depend on overly optimistic clinical, regulatory, manufacturing or commercial assumptions.
The companies that create the most value will be those that treat M&A as more than a transaction. They will link target selection to portfolio strategy, conduct rigorous clinical and commercial diligence, structure deals to share risk appropriately and plan integration early enough to preserve the target’s innovation engine. In Life Sciences, the winners will not simply be the companies that buy the most assets; they will be the companies that know which assets to buy, how much risk to accept and how to turn scientific promise into sustainable patient and shareholder value.
ISG helps Life Sciences companies navigate M&A activity to ensure the business value, timely execution of TSAs and increased rigor to capture savings and manage associated risk. Contact us to find out how we can help your organization.
About the authors
Brant Bertrand
Anamika Sarkar
Anamika Sarkar works as a Manager in ISG. She has close to 11 years of experience in research across various industries and geographies. At ISG, Anamika helps Manufacturing enterprises understand the latest technology trends, strategy, and innovation.
